NOVEL MIXED μ AGONIST/ δ ANTAGONIST OPIOID ANALGESICS WITH REDUCED TOLERANCE LIABILITIES AND USES THEREOF
申请人:COOP Andrew
公开号:US20160016965A1
公开(公告)日:2016-01-21
An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects. The present invention includes 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor, along with analogs of morphine, dihydromorphine, hydromorphone, codeine, dihydrocodeine, hydrocodone and ethylmorphine. Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compound sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols. UMB 425 exhibits a mixed μ agonist/δ antagonist profile as determined in receptor binding. UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.
一种阿片类麻醉药物,用于治疗中度到重度疼痛,主要通过μ受体发挥其镇痛作用。尽管传统的μ激动剂可能会引起不良反应,包括耐受性,但加入δ拮抗剂可以减轻这些不良反应。本发明包括4a,9-二羟基-7a-(羟甲基)-3-甲基-2,3,4,4a,5,6-六氢-1H-4,12-甲烷基苯并呋喃[3,2-e]异喹啉-7(7aH)-酮(UMB 425),一种基于5,14-桥接吗啡的奥维诺前体,以及吗啡,二氢吗啡,羟吗啡,可待因,二氢可待因,氢可酮和乙基吗啡的类似物。虽然UMB 425缺乏δ特异性基序,但μ和δ受体的构象采样药效模型预测其在μ受体上具有类似吗啡的功效,在δ受体上具有类似于纳曲酮的功效,因为化合物采样与奥维诺尔类似的构象,其中羟基部分与受体相互作用。UMB 425在受体结合中表现出混合的μ激动剂/δ拮抗剂特性。UMB 425在体外表现出混合的μ激动剂/δ拮抗剂特性,这种特性在体内可转化为降低耐受性的效果。